Clinical Trials Arena on MSN16h
IGC Pharma posts promising interim data for Alzheimer’s therapyThe results suggest that IGC-AD1 may decrease the frequency and severity of sleep disturbances and night time behaviours.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback